Sirolimus-containing graft-versus-host disease prophylaxis in patients with lymphoma.
Mehta
Jayesh
J
D065095:Calcineurin Inhibitors; D018572:Disease-Free Survival; D006086:Graft vs Host Disease / Q000209:etiology / Q000517:prevention & control*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D053208:Kaplan-Meier Estimate; D008223:Lymphoma / Q000601:surgery*; D008727:Methotrexate / Q000627:therapeutic use*; D020123:Sirolimus / Q000627:therapeutic use*; D019172:Transplantation Conditioning / Q000009:adverse effects; D014184:Transplantation, Homologous; D016896:Treatment Outcome
D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; D020123:Sirolimus; D008727:Methotrexate